Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
Protein Name: | PLCB2 |
Gene Name: | PLCB2 |
Protein Full Name: | 1-phosphatidylinositol-4,5-bisphosphate phosphodie |
Alias: | 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta 2; FLJ38135; Phosphoinositide phospholipase C; Phospholipase C- beta-2; Phospholipase C, beta 2; PLC-beta-2 |
Mass (Da): | 134024 |
Number AA: | 1185 |
UniProt ID: | Q00722 |
Locus ID: | 5330 |
COSMIC ID: | PLCB2 |
Gene location on chromosome: | 15q15 |
Cancer protein type: | OP |
Effect of cancer mutation on protein: | UNCLEAR |
Effect of active protein on cancer: | PROMOTES |
Number of cancer specimens: | 19850 |
Percent of cancer specimens with mutations: | 0.87 |
Normal role description: | This phospholipase is activated by trimeric G-protein subunits and generates DAG and IP3 from PIP2. Therefore, PLCB2 generates important second messengers in cellular signalling. Analysis of breast cancer tumors demonstrates that increasing PLCB2 expression correlates with loss of differentiation and worse prognosis. This supports the theory that proteins downstream of the IP3/DAG signalling pathway promote oncogenesis. |